Veozah Vms denied as experimental or investigational by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for veozah vms are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UHC May Deny Veozah for VMS as Experimental

Veozah (fezolinetant) received FDA approval in May 2023 as the first neurokinin 3 (NK3) receptor antagonist indicated for moderate-to-severe vasomotor symptoms (hot flashes) associated with menopause. Despite this approval, UnitedHealthcare may initially categorize newer drugs as "experimental or investigational" if their internal coverage policy has not yet been updated to reflect the approval, or if UHC applies additional coverage criteria beyond FDA approval that the submission did not yet address.

## Why This Is Appealable

An FDA-approved drug used within its approved indication cannot legally be classified as experimental under the ACA and ERISA. The experimental/investigational denial standard applies to drugs that lack FDA approval or are being used outside an approved indication. Fezolinetant has full FDA approval for moderate-to-severe VMS due to menopause. If UHC's denial rests solely on an outdated internal policy or a misclassification, the denial is directly contradicted by the drug's regulatory status and is highly likely to be overturned on appeal.

## Federal Appeal Framework

• Internal appeal (ACA/ERISA §503): This denial type is among the most reversible on internal appeal. Submit the FDA approval letter/label and the indication language immediately. Decisions are typically required within 30 days for standard or 72 hours for expedited requests.
• Expedited appeal: Request if VMS symptoms are severe and significantly impairing work or sleep.
• External review (ACA §2719): If the internal appeal is denied, escalate to independent external review within approximately four months. Independent reviewers apply objective clinical standards and are not bound by UHC's internal policy classification. Experimental denials of FDA-approved drugs are frequently reversed at external review.

## Documentation to Gather

1. FDA approval documentation: A copy of or citation to the FDA approval and the official prescribing label (package insert) for Veozah, confirming the approved indication matches your diagnosis. 2. Diagnosis confirmation: Clinical documentation of menopause diagnosis and moderate-to-severe VMS (frequency, severity, functional impact) from office notes. 3. UHC's current coverage policy: Request the exact policy and clinical criteria UHC used to make this determination. If their policy predates the FDA approval or uses outdated language, that is a core argument. 4. Prescriber medical-necessity letter: Confirming the on-label use, the clinical severity, and requesting that UHC apply its coverage criteria consistent with the drug's FDA-approved status. 5. Professional society guidance: Reference from the relevant professional society (e.g., the Menopause Society/NAMS) supporting fezolinetant as a recognized non-hormonal treatment option.

## Criteria-Mapping Structure for Your Appeal Letter

| Experimental/Investigational Criterion | Your Rebuttal | |---|---| | Drug lacks FDA approval | Cite FDA approval date and indication | | Use is outside approved indication | Confirm diagnosis matches the approved indication exactly | | No established clinical evidence | Reference the FDA approval basis; cite the relevant professional society guideline | | UHC coverage policy excludes this drug | Request updated policy; argue policy must be consistent with FDA status |

The strongest experimental-denial appeals anchor every argument to the FDA approval language and the prescribing label — include both as attachments.